Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | TOP1 | P11387 | 2/20 | 0.41 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535766 | 0.86 | CHRM1 (0.68) | CHRM1TOP1LMNA | |
| SCHEMBL16378027 | 0.82 | CHRM1 (0.76) | CHRM1HTTGNRHRKDM4EALDH1A1 | |
| SCHEMBL1931751 | 0.82 | CHRM1 (0.60) | CHRM1HTTP2RX3GNRHRKDM4E | |
| SCHEMBL3234195 | 0.81 | CHRM1 (0.58) | CHRM1HTTP2RX3GNRHRKDM4E | |
| SCHEMBL1666185 | 0.80 | CHRM1 (0.44) | CHRM1JAK2JAK3P2RX3TOP1 | |
| SCHEMBL11895782 | 0.80 | CHRM1 (0.55) | CHRM1P2RX3TOP1LMNA | |
| SCHEMBL1668388 | 0.79 | CHRM1 (0.61) | CHRM1JAK2JAK3P2RX3TOP1 | |
| SCHEMBL3234568 | 0.78 | CHRM1 (0.51) | CHRM1HTTGNRHRLMNAKDM4E | |
| SCHEMBL22416058 | 0.78 | CNR1 (0.52) | CHRM1 | |
| SCHEMBL1665806 | 0.78 | P2RX3 (0.51) | CHRM1JAK2JAK3P2RX3TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312949-B1 | N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, OPRM1 | CHRM1 1/4885HTT 467/4885JAK2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.